Vitrisa Therapeutics is a privately held, preclinical stage, biotech company headquartered in the San Francisco Bay Area.
The company is focused on a proprietary suite of technologies for the discovery & development of optimized ocular therapeutics with the potential to address the underlying mechanisms of vision loss in a wide range of ocular diseases.
Our goal is to bring therapeutics that preserve or restore vision to people suffering from sight threatening ocular diseases - with an initial emphasis on orphan and rare pediatric ocular indications.
Company Details
- Address
- 700 Larkspur Landing Circle, Larkspur,california 94939,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vitrisatherapeutics.com
- Keywords
- Morrisville.
- HQ
- Larkspur, California
Vitrisa Therapeutics Questions
Vitrisa Therapeutics's website is vitrisatherapeutics.com
Vitrisa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/vitrisa-therapeutics
Vitrisa Therapeutics's industry is
Biotechnology Research
Vitrisa Therapeutics's top competitors are
Insitro,
Drive Therapeutics,
Medna Dx,
Oak Bay Biosciences, Inc.,
Rivercyte,
Abbiouk,
Creyon Bio,
Angelman Syndrome Biomarker And Outcome Measure Consortium,
Ermaris Bio,
Lean Works Llc.
Vitrisa Therapeutics's categories are Biotechnology Research
